Tiziana Life Sciences’ intranasal drug has hit the dual endpoints of a phase 2a study in patients with a form of multiple sclerosis (MS), although the win was slightly marred by the higher dose ...

Teva has given up on a key trial of one of its original lineup of innovative medicines. | Teva has given up on a key trial of ...

The PASI 90 rate, which is in line with the phase 2 result, looks competitive. Cross-trial comparisons can be unreliable, ...

The FDA has put a partial hold on Biosciences’ seizure study application over preclinical toxicity data and concerns about ...

The FDA has accepted uniQure’s applicatoin for its Huntington’s disease gene therapy under priority review, alongside a tentative plan to convene an advisory committee meeting. | The FDA has accepted ...

Eli Lilly’s triple-G drug candidate retatrutide has beaten Novo’s Ozempic in a head-to-head phase 3 trial, driving deeper ...

The drug programs left behind after Jazz Pharmaceuticals' $820 million acquisition of Actio Biosciences have found a new home ...

Audax sees the propensity for IL-12 drugs to bind receptors on peripheral immune cells as a driver of the dosing and toxicity ...

Eli Lilly has dropped its phase 2 Alzheimer's disease program for mevidalen, marking another setback for the experimental ...

BioMarin is paying $70 million upfront to license a Fabry disease drug candidate, expanding the franchise it acquired through ...

During a public hearing Wednesday to discuss a newly proposed rare disease framework, FDA center director Michael Davis, M.D.

“If Powerful AI is directed at solving humanity’s hardest problems and the risks are managed responsibly, the potential is ...